99.9%, Nasdaq listing.....
Reply to some private messages.....
99.9%: There have been instances in the past where the identity of the China company vended into a shell turned out to be different from what I was expecting. Which is why I am only 99.9% certain Daqing Morinaga is the RM candidate, rather than 100% certain.
For example, SCLX (coal water) was originally suppose to have been vended into a certain shell. Everything was set to go, however just prior to the RM the Chinese management team made a trip to the United States and at that time the consultant made a basically last minute/week decision to switch shells.
What makes CCKH somewhat unique versus other types of situations I've seen/experienced in the past is that there are corporate actions and SEC filings that are actually helping confirm in my mind that Daqing Morinaga is the RM candidate. In past situations, the information on the Chinese websites was usually the only thing I could rely on (China company A is reverse merging with Shell B). However, with CCKH we not only have the information that can be found on the Chinese websites but we have US-based actions/filings that seem to heavily support that information.
IMO, so far everything appears to pointing toward Daqing Morinaga.....
1) The name change to "China Domestica Bio-technology Holdings" has an obvious reference/application to the term "housefly".
2) The name of the BVI holding company that purchased the shell has an obvious similiarity to what I believe is the name of the mainland China company that controls Daqing Morinaga.
3) The controlling person of both the BVI company and DM are the same person.
4) The date on the news item in the post I am responding to corresponds nicely with the dates on the sale of the CCKH shell and the accompanying 8-K filing.
5) And, of course, that Chinese Chamber of Commerce website in March specifically mentions CCKH (see post #189)......
China Fly biomedical holding company is specialized in housefly insect active protein in the field of applied biomedical R & D, production and sales of high-tech biological pharmaceutical enterprises, the company of "science and technology to create a healthy, professional win the trust" business purposes, adhere to standards, the state of the high standards of philosophy as a guide, the product-oriented scientific research, patents, technology, innovation, relying on high-technology industries development. Company in the U.S. Nasdaq (NASDQ) successfully listed, listed code: CCKH.OB): Headquartered in Shenzhen, the company invested in 330 million yuan in Fuzhou, Jiangxi Fuzhou Sheng Yongsheng materials Pharmaceutical Co., Ltd. was established to build national CD the activity of a protein biomedical industry park.
Nasdaq listing: The language in the above news snippet and that Chamber of Commerce website is consistent with what I usually see. Chinese websites quite often refer to a reverse merger with a Bulletin Board shell as being "successfully listed on Nasdaq". I don't think it is something done to intentionally deceive investors; it is just sort of an idiosyncrasy you become accustomed to when dealing with China reverse mergers.
News 
Market Data 
Discover 
